Skip to main content
Home
User account menu
  • IRBManager
  • CTSU
Main navigation
  • Home
  • About
    • Our Mission
    • Our History
    • Who’s Involved
    • About the Boards
      • Adult CIRB - Late Phase Emphasis Members
      • Adult CIRB - Early Phase
      • Pediatric CIRB
      • Cancer Prevention and Control CIRB
    • CIRB SOPs
    • List of Institutions
    • Studies
  • For New Users
    • Overview of the Study Review Process
    • Frequently Asked Questions about Navigating IRBManager
    • When To Use NCI CIRB, IRBManager, and CTSU Websites
  • For Institutions
    • IRBManager Basics
    • Overview of the Study Review Process
    • Becoming A Signatory Institution
    • Navigating The CIRB For NCI Division of Cancer Prevention (DCP) Consortia Sites And Cancer Prevention Clinical Trial Network (CP-CTNET) Organizations
    • Create and Update the Signatory Institution Worksheet
      • Completing The Annual Signatory Institution Worksheet
      • Establishing Your Signatory Institution
      • Short Form Q & A
    • Creating and Updating the Annual Principal Investigator Worksheet
      • Establishing a Principal Investigator
    • How to Open a Study
      • Opening a Study
    • Change the PI on a Study
      • Changing the PI on a Study
    • Submit a Study Closure
    • Report A Potential Unanticipated Problem Or A Serious Or Continuing Noncompliance
    • Request an Assent Waiver
      • Completing The Assent Waiver Worksheet
    • Notify the CIRB about the participation of an incarcerated participant
      • Completing The Notification of Incarcerated Participant Worksheet
      • Institution Q & A
      • Boilerplate Language Q & A
      • Finding Information Q & A
      • Guidelines For Permitted Boilerplate Language Additions
      • Individual Roles Within The CIRB
      • Institutions' Roles With The CIRB
      • Managing Your CTEP Registration
      • Oversight Q & A
      • Updating Your CIRB Institution Roster using RUMS
      • Updating Your CIRB Person Roster using RUMS
      • Viewing Your CIRB Roster
  • For Networks
    • Overview of the Study Review Process
    • CIRB Document Posting
    • Submitting Studies
      • Completing The Translation Application
      • Completing The Unanticipated Problem And/Or Serious or Continuing Noncompliance Submission Application
      • Completing The Waiver Of Consent Application
      • Determining Waiver Of Consent Requirements
      • End User Licensing Agreement (Eula) Consent Form Language Q & A
      • Review of Translated Consent Forms, PROs, and Other Patient-Facing Documents
      • Submitting Recruitment/participant Materials For Review
    • CIRB Meeting Schedules
  • For Board Members
    • Become A Board Member
    • Overview of the Study Review Process
    • Resources
      • Helpful URLs
      • IRBManager Training for Board Members
    • CIRB Meeting Schedules
  • Contact Us

FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic - Guidance for Industry, Investigators, and Institutional Review Boards

  • Read more about FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic - Guidance for Industry, Investigators, and Institutional Review Boards

Memorandum on Additional Guidance for Clinical Trial Activities Affected by the Novel Coronavirus

  • Read more about Memorandum on Additional Guidance for Clinical Trial Activities Affected by the Novel Coronavirus

Memorandum on Additional Guidance for Clinical Trial Activities Affected by the Novel Coronavirus

  • Read more about Memorandum on Additional Guidance for Clinical Trial Activities Affected by the Novel Coronavirus

Memorandum on Interim Guidance for Patients on Clinical Trials Supported by the NCI Cancer Therapy Evaluation Program and the NCI Community Oncology Research Program (NCORP)

  • Read more about Memorandum on Interim Guidance for Patients on Clinical Trials Supported by the NCI Cancer Therapy Evaluation Program and the NCI Community Oncology Research Program (NCORP)

Interim Guidance for Patients on Clinical Trials Supported by the NCI DCP Phase 0-2 Cancer Prevention Clinical Trials Program

  • Read more about Interim Guidance for Patients on Clinical Trials Supported by the NCI DCP Phase 0-2 Cancer Prevention Clinical Trials Program

Oversight Questionnaire

  • Read more about Oversight Questionnaire

Study-Specific Worksheet

  • Read more about Study-Specific Worksheet

Study Closure and Transfer Worksheet

  • Read more about Study Closure and Transfer Worksheet

Principal Investigator Worksheet

  • Read more about Principal Investigator Worksheet

Carousel_1

  • Read more about Carousel_1

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 203
  • Page 204
  • Page 205
  • Page 206
  • Current page 207
  • Page 208
  • Page 209
  • Page 210
  • Page 211
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to
Close

The NCI Central Institutional Review Board

401 N. Washington Street, Ste. 700
Rockville, MD 20850

The Central Institutional Review Board for the National Cancer of Institute is fully accredited by the Association for the Accreditation of Human Research Protection Program, Inc.